Topic: Management of Hepatocellular Carcinoma

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 31 Aug 2018

Share This Special Issue

Guest Editor(s)

  • Osamu Yokosuka, MD
    Chiba University, Department of Medicine and Clinical Oncology, Chiba, Japan.


Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Aug, 2018
Contacts: Siqi Li, Assistant Editor,

Published Articles Download All Articles
  • Thermal ablation of large unresectable hepatocellular carcinoma in cirrhotic patients

    Giovan Giuseppe Di Costanzo , Raffaella Tortora , Anna Opramolla , Marco Guarracino
    Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Surgery is the mainstay of treatment, but less than 20%-30% of patients are good candidates. Actually, thermal ablation is considered the best treatment with curative intent for cirrhotic patients with unresectable HCC ≤ 3 cm. Unfortunately, radio frequency efficacy in obtaining the complete ablation of HCC nodules diminishes with increasing tumor size and local tumor progression is more frequent in larger nodules. To overcome these problems, higher-powered generators, different devices and... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:53. | doi:10.20517/2394-5079.2018.56
    Published on: 17 Sep 2018  | Viewed:13  | Downloaded:1
    +HTML| PDF
  • Cancer immunotherapy for hepatocellular carcinoma

    Joo-Ho Lee , Soo-Yeon Oh , Jin Yong Kim , Naoshi Nishida
    Most hepatocellular carcinomas (HCCs) arise on a background of chronically inflamed liver, and thus are considered typical immunogenic cancers. Although there have been advances in treatment options for HCC, many patients still struggle with a limited chance of survival requiring further innovative approach. Especially for the advanced HCC, many other molecular targeted therapies had been evaluated without success. Based on the immunological mechanisms thought to be acting during HCC development, the effects of diverse immunomodulatory regimens such as therapeutic vaccination, immune... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:51. | doi:10.20517/2394-5079.2018.78
    Published on: 10 Sep 2018  | Viewed:259  | Downloaded:25
    +HTML| PDF
  • Hepatic resection for hepatocellular carcinoma

    Shun Yamaguchi , Taichiro Kosaka , Susumu Eguchi
    Hepatic resection has become the standard treatment of primary liver cancer. Indications for hepatic resection in patients with hepatocellular carcinoma (HCC) vary greatly between Japan and other countries because the clinical practice guidelines for HCC defined by the Japan Society of Hepatology differ from the EASL-EORTC clinical practice guidelines. Hepatic resection is not recommended as a treatment for the patients at Barcelona Clinic Liver Cancer (BCLC) stage B. Otherwise, there are many surgeons/clinicians who believe that not all HCC patients at BCLC stage B should be excluded from... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:50. | doi:10.20517/2394-5079.2018.68
    Published on: 22 Aug 2018  | Viewed:455  | Downloaded:38
    +HTML| PDF
  • Hypofractionated ablative radiation therapy for hepatocellular carcinoma: practical considerations and review of the literature

    Marsha Reyngold , Eugene J. Koay , Christopher H. Crane
    Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. The prognosis for patients who present with inoperable primary liver tumors is poor with median survival times of 12 months or less. Tumor-related liver failure is a common cause of mortality, underscoring the importance of local control. Recent advancements in external beam radiation therapy delivery techniques have enabled dose escalation that in turn has significantly improved local control and has allowed radiation therapy to emerge as an effective modality in this setting. In this review, we outline the... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:49. | doi:10.20517/2394-5079.2018.84
    Published on: 20 Aug 2018  | Viewed:725  | Downloaded:66
    +HTML| PDF
  • Laparoscopic liver resection for hepatocellular carcinoma

    Massimo Giacca , Daniel Cherqui
    Hepatocellular carcinoma (HCC) represents the most common indication of laparoscopic liver resection (LLR). It must be acknowledged that most series concern minor hepatectomies for peripheral lesions located in favorable segments, and such procedures are now performed in the majority of HPB centers. However, there are growing reports concerning major hepatectomies (i.e., 3 segments or more) and complex resections such as anatomical resections in difficult segments (i.e., postero-superior). Retrospective comparative studies, including some with propensity score matching, and meta-analyses... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:47. | doi:10.20517/2394-5079.2018.79
    Published on: 17 Aug 2018  | Viewed:385  | Downloaded:31
    +HTML| PDF
  • Exosome-based liquid biopsy in the management of hepatocellular carcinoma

    Aparna Jayachandran , Sasidhar Venkata Manda , Ritu Shrestha , Kim R. Bridle , Prashanth Prithviraj , Darrell H. G. Crawford
    Hepatocellular carcinoma (HCC) commonly presents at an advanced stage due to the lack of efficient early screening tools. Early, non-invasive biomarkers useful in the diagnosis and prognosis of HCC would be of significant benefit for HCC management. Development of exosome-based liquid biopsy as a non-invasive method for the management of HCC has gained much traction. Exosomes are small membranous vesicles secreted by most cell types including HCC cells. Exosomes serve as couriers for the intercellular transfer of important biomolecules, including, protein, nucleic acids and lipids to nearby... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:44. | doi:10.20517/2394-5079.2018.59
    Published on: 13 Aug 2018  | Viewed:460  | Downloaded:61
    +HTML| PDF
  • Living donor liver transplantation for patients with hepatocellular carcinoma in Japan

    Yasuhiko Sugawara , Hidekazu Yamamoto , Taizo Hibi
    Liver transplantation has now been an established treatment for hepatocellular carcinoma and cirrhosis. The Milan criteria have been accepted and applied widely in the world as an indication for deceased donor liver transplant. Due to the severe organ shortage, however, living donor liver transplant (LDLT) has accounted for the majority of transplantations in Japan and the other Asian countries/regions. LDLT cannot be limited by the restrictions imposed by the allocation system but depends on institutional criterion or case-by-case considerations. Accumulating data from a nationwide survey... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:33. | doi:10.20517/2394-5079.2018.69
    Published on: 10 Jul 2018  | Viewed:249  | Downloaded:12
    +HTML| PDF
  • Hepatocellular carcinoma in patients without cirrhosis: relevance and clinical characteristics

    Kellyane Santana Dias Carvalho , Luciano E. Fonseca , Helma P. Cotrim
    Aim: The present study evaluated the frequency of hepatocellular carcinoma (HCC) in patients without cirrhosis. Methods: HCC patients were recruited from two reference centers for liver disease in Northeast Brazil from 2010 to 2016. The diagnosis of HCC and cirrhosis was based on international criteria.Results: A total of 169 patients were included, and 16% (27) of the patients did not have hepatocellular carcinoma in non-cirrhosis (HCC-NC). The mean age of HCC-NC was 64.4 ± 11.3 years, and 74.1% of the patients were male. The main risk factors were hepatitis C virus (HCV) in 29.6% (8),... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:15. | doi:10.20517/2394-5079.2018.13
    Published on: 29 May 2018  | Viewed:512  | Downloaded:48
    +HTML| PDF
  • Systemic therapies for hepatocellular carcinoma: a recap of the current status

    Petros Giovanis , Manuela De Bona , Fabio Farinati , Andrea Buda , Riccardo Berletti , Fable Zustovich , Simona D’Ippolito , Michele De Boni , Umberto Cillo , Davide Pastorelli
    After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data: lenvatinib resulted not inferior to the standard of care sorafenib in first line, regorafenib and cabozantinib demonstrated prolonging survival in patients progressed to sorafenib and nivolumab approved by FDA as option after first-line. Contemporary, the knowledge acquired after ten years’... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:10. | doi:10.20517/2394-5079.2018.21
    Published on: 27 Apr 2018  | Viewed:1268  | Downloaded:127
    +HTML| PDF
  • A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma

    Denise Cerqueira Paranaguá-Vezozzo , Celso Eduardo Lourenço Matielo , Daniel Ferraz de Campos Mazo , Lucas Souto Nacif , Mario Guimaraes Pessoa , Gleicy Luz Reinoso Pereira , Roque Gabriel Rezende de Lima , Patricia Momoyo Yoshimura Zitelli , Suzane Kioko Ono , Flair José Carrilho
    Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including 93 patients: 31 with small diameter HCC and 62 without HCC. Groups were matched by age and gender. Multiple logistic regression analysis using Akaike Information Criteria to estimate the probability of HCC was performed. A model score was generated and bootstrap analysis was performed for internal... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:11. | doi:10.20517/2394-5079.2018.17
    Published on: 27 Apr 2018  | Viewed:870  | Downloaded:67
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.